Enhanced immunogenic potential of cancer immunotherapy antibodies in human IgG1 transgenic mice

• Main Authors: Jerome Egli (Author), Stefan Heiler (Author), Felix Weber (Author), Guido Steiner (Author), Timo Schwandt (Author), Katharine Bray-French (Author), Christian Klein (Author), Sebastian Fenn (Author), Gregor P. Lotz (Author), Eugenia Opolka-Hoffmann (Author), Thomas E. Kraft (Author), Laetitia Petersen (Author), Rebecca Moser (Author), Jonathan DeGeer (Author), Michel Siegel (Author), Daniela Finke (Author), Juliana Bessa (Author), Antonio Iglesias (Author)
• Format: Book
• Published: Taylor & Francis Group, 2022-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Clinical anti-drug-antibody (ADA) responses represent a substantial obstacle to the development of efficacious therapeutic antibodies. The enhanced ADA production against the idiotype (Id) often displayed by cancer immunotherapy antibodies (CitAbs) can lead to exposure loss and subsequently affect a...